Precision Medicine

Kala Bio's new deal with Virotek isn't just about eye care. It's a capital-efficient pivot that tests its new identity and bets on a commercial present.

The Israeli biotech firm gained crucial FDA feedback for its personalized therapy, NewRal. But in a field laden with failure, is this a true breakthrough?

Northway Biotech's new Vilnius hub isn't just a factory; it's a strategic move to dominate Europe's advanced therapy market. A deep dive into the investment.

Life Line Screening's p-tau217 test democratizes Alzheimer's risk assessment, raising critical questions about non-diagnostic data and patient well-being.

By appointing two legendary specialists, XGEN isn't just shuffling its board. It's aiming to legitimize whole genome sequencing for all IVF patients.

As Alamar Biosciences prepares for a key fireside chat at Morgan Stanley, all eyes are on its NULISA™ technology and its rapid commercial growth.

Beyond the pink ribbons, the CIBC Run for the Cure is a funding powerhouse. We unpack the 30-year alliance that's fueling AI-driven diagnostics and policy battles.

A $10M federal contract aims to slash the 7-year wait for rare disease diagnoses. Discover how Probably Genetic's AI and direct-to-patient data are leading the charge.

A strategic merger combines Chemomab's promising drug, nebokitug, with Scipher's AI platform, aiming to de-risk development and transform RA treatment.

XYRA's new trial uses data from wearables to personalize doses of Budiodarone, a safer alternative to today's standard AF drugs. Is this the future?

A landmark UCSF study has mapped the molecular machinery of autism, revealing convergent pathways. This isn't just a breakthrough for ASD; it's a new model for drug discovery.

As precision medicine generates a deluge of data, Iylon Oncology's appointment of Dr. Mary Lopresti shows the real value is not in the algorithm, but in human expertise.

A new FDA approval for Roche's HER2 tests paves the way for a powerful new drug, offering hope to patients with aggressive gastroesophageal adenocarcinoma.

A landmark study reveals that children of centenarians inherit a powerful biological advantage, rewriting our understanding of aging, health, and longevity.

A new partnership merges genetic screening and sperm analysis, promising empowered family planning. But as data deepens, are we crossing an ethical frontier?

From stroke pioneer to lung disease disruptor, Brainomix's new AI studies signal a major shift in diagnostics. This is the story behind the numbers.

FDA clearance for Roche's pTau217 blood test isn't just a clinical win; it's a strategic move to dominate a $27B market by making diagnosis simple and scalable.

Telix's impressive H1 results show more than just profit; they reveal a calculated strategy to build a global radiopharmaceutical powerhouse.

A new trial for refractory melanoma relies on a breakthrough manufacturing platform from NTx Bio. This is how automation is making personalized vaccines a reality.

The ALS Association's premier conference unites patients, researchers, and advocates to tackle the disease from the lab bench to the insurance appeal.